Botanical species · safety record

Zygophyllum fabago

The EFSA Compendium of Botanicals holds 8 constituent measurements for Zygophyllum fabago. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Zygophyllum fabago L.

8Constituent measurements
0Safety records
7Cited sources
0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

  • Pentacyclic triterpene saponins4
  • Alkaloids1
  • Harman1
  • Phenylpropanoids1
  • Saponins1

Plant parts

  • Roots and other underground parts3
  • Bark2
  • Aerial part of plants1
  • Live plants1
  • Unspecified1

Preparations

  • Solvent extraction5

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
Pentacyclic triterpene saponinsAerial part of plantsSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI
Pentacyclic triterpene saponinsRoots and other underground partsSolvent extractionChromatographic testsResolve DOI
Pentacyclic triterpene saponinsBarkSolvent extractionHPLC with standard detection methodsResolve DOI
AlkaloidsRoots and other underground parts0.058 PercentColorimetry, Spectroscopy (Spectrometry) and PhotometryNo resolvable identifier
HarmanRoots and other underground parts0.014 PercentColorimetry, Spectroscopy (Spectrometry) and PhotometryNo resolvable identifier
Pentacyclic triterpene saponinsBarkSolvent extractionHPLC with standard detection methodsNo resolvable identifier
PhenylpropanoidsLive plantsSolvent extractionNuclear Magnetic Resonance (NMR)No resolvable identifier
SaponinsUnspecified120 Gram/kilogramUnspecifiedNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Fatkulin, A. G., Abramov, M. M., Otroshchenko, O. S., Sadykov, A. S. Chemical composition of Zygophyllum fabago. Trudy samarkandskogo gosudarstvennogo universiteta imeni alishera navoi, 1969, p. 147-153.
  2. He, Jiangbo., Lv, Xiaoman., Niu, Yanfen., Tao, Jian., Wang, Bo., Jia, Jing., Chen, Weiwei. Four new compounds from Zygophyllum fabago L.. Phytochemistry letters, 2016, p. 116-120.
  3. Feng, Yu-Lin., Li, He-Ran., Rao, Yi., Luo, Xiao-Jian., Xu, Li-Zhen., Wang, Yue-Sheng., Yang, Shi-Lin., Kitanaka, Susumu. Two Sulfated Triterpenoidal Saponins from the Barks of Zygophyllum fabago L.. CHEMICAL & PHARMACEUTICAL BULLETIN, 2009, vol. 57, no. 6, p. 612-614.
  4. Khan, Saleha Suleman., Khan, Ajmal., Khan, Afsar., Wadood, Abdul., Farooq, Umar., Ahmed, Amir., Zahoor, Aqib., Ahmad, Viqar Uddin., Sener, Bilge., Erdemoglu, Nurgun. Urease inhibitory activity of ursane type sulfated saponins from the aerial parts of Zygophyllum fabago Linn. PHYTOMEDICINE, 2014, vol. 21, no. 3, p. 379-382. DOI
  5. Kerimova, Kh.M., Pkheidze, T.A., Gorovits, T.T. Triterpene saponins of Zygophyllum fabago. Chemistry of Natural Compounds, 1971, vol. 7, no. 4, p. 521-None. DOI
  6. Feng, Yu-Lin., Wu, Bei., Li, He-Ran., Li, Yun-Qiu., Xu, Li-Zhen., Yang, Shi-Lin., Kitanaka, Susumu. Triterpenoidal saponins from the barks of Zygophyllum fabago L.. CHEMICAL & PHARMACEUTICAL BULLETIN, 2008, vol. 56, no. 6, p. 858-860. DOI
  7. Borkowski, Boguslaw. Chromatographic determination of alkaloids in Zygophyllum fabago. Biuletyn instytutu roslin leczniczych, 1959, p. 158-168.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue